MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-7117
Drug: Placebo

First Posted Date: 2016-07-15

Last Posted Date: 2017-07-25

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 144

Registration Number: NCT02834442

Locations: 🇬🇧
Investigational center, United Kingdom, United Kingdom

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

Phase 1

Completed

Conditions: Vasomotor Symptoms

Interventions: Drug: MT-8554 low dose
Drug: MT-8554 middle dose
Drug: MT-8554 high dose
Drug: Placebo

First Posted Date: 2016-06-16

Last Posted Date: 2017-02-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 24

Registration Number: NCT02803268

Locations: 🇩🇪
Investigational center, City name, Germany

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: MT-3995 High
Drug: MT-3995 Low
Drug: MT-3995 Middle

First Posted Date: 2016-02-08

Last Posted Date: 2017-09-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 241

Registration Number: NCT02676401

Locations: 🇯🇵
Touei Hospital, Hokkaido, Japan

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-8554
Drug: rosuvastatin
Drug: simvastatin

First Posted Date: 2016-02-05

Last Posted Date: 2016-03-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 28

Registration Number: NCT02675309

Locations: 🇬🇧
Investigational center, City name, United Kingdom

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Canagliflozin (TA-7284)
Drug: Insulin

First Posted Date: 2015-12-04

Last Posted Date: 2019-04-10

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 139

Registration Number: NCT02622113

Locations: 🇯🇵
Reserch site, Tohoku, Japan

A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-8554 low dose
Drug: MT-8554 high dose
Drug: Oxycodone hydrochloride
Drug: Placebo

First Posted Date: 2015-08-31

Last Posted Date: 2016-01-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 20

Registration Number: NCT02536209

Locations: 🇬🇧
Investigational center, City name, United Kingdom

Drug Interaction Study of Warfarin and MT-3995

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Warfarin
Drug: MT-3995

First Posted Date: 2015-08-24

Last Posted Date: 2015-10-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 20

Registration Number: NCT02531568

Locations: 🇩🇪
Clinical research organization, Neu-Ulm, Wegenerstraße, Germany

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: MT-3995 Low
Drug: MT-3995 High
Drug: Placebo
Drug: MT-3995 Middle

First Posted Date: 2015-08-07

Last Posted Date: 2017-03-03

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 293

Registration Number: NCT02517320

Locations: 🇯🇵
Investigational site, Hokkaido, Japan

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-8554
Drug: Placebo

First Posted Date: 2015-04-29

Last Posted Date: 2016-01-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 135

Registration Number: NCT02429102

Locations: 🇬🇧
Investigational center, City name, United Kingdom

Extension Study of MT-1303 in Subjects With Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: MT-1303

First Posted Date: 2015-03-17

Last Posted Date: 2017-09-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 46

Registration Number: NCT02389790

Locations: 🇺🇦
Investigational site, City Name, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy